![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 30, 2023
At a recent meeting, ECOG-ACRIN leaders and members celebrated the conclusion of enrollment to the landmark NCI-MATCH clinical trial
June 30, 2023
This phase 3 study aims to determine the optimal sequencing of surgery, chemotherapy, and chemoradiotherapy for patients with cancer of the penis
April 19, 2023
The ComboMATCH registration trial opens; NCI creates Clinical Trials Innovation unit, unveils revised National Cancer Plan
February 10, 2023
Plans for the year ahead; a focus on data; the future of cancer screening studies
December 20, 2022
Reflections on NCI-MATCH and its successor trials; research results in leukemia and breast cancer; and grant renewal preparations
December 20, 2022
This study is investigating the safety and efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory ALL population
December 20, 2022
In July, the field of radiation oncology lost an expert and pioneer
December 20, 2022
In November, the field of breast cancer research lost a revolutionary
December 20, 2022
In an annual evaluation, 36 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
December 20, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
October 13, 2022
Research results in breast and kidney cancer; recognition of key colleagues; and a sneak peek of the Fall 2022 Group Meeting
August 16, 2022
President Biden to appoint Dr. Monica Bertagnolli as NCI Director; NCI-MATCH trial data leads to FDA drug approval